PET in clinical routine: Financial and industrial implications;La tomographie d'emission de positons en routine clinique: Perspective d'impact financier et industriel

RBM - Revue Europeenne de Technologie Biomedicale

Volumn 20, Issue 7, 1998, Pages 180-182

  Fauchet, M ^a   Vernon, J D ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Investments PET; Oncology needs

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEALTH INSURANCE; HUMAN; POSITRON EMISSION TOMOGRAPHY; REIMBURSEMENT; SHORT SURVEY;

EID: 0032230193     PISSN: 02220776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0222-0776(98)80023-0     Document Type: Article

References (5)

1. 18F-FDG: Approche cout/efficacite
2. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma
3. Cost-effectiveness of PET imaging in clinical oncology
4. La TEP en routine clinique : Impact economique